1986) reported that the effects of an ethanol extract of the plant Sophora flavescens Ait possessed antiarrhythmic
Efficacy of sequential antiarrhythmic
treatment in sinus rhythm maintenance after successful electrocardioversion in patients with chronic non-valvular atrial fibrillation.
Drugs as First-Line Treatment of Symptomatic Atrial Fibrillation) study.
The administration of levofloxacin when significant bradycardia, hypokalemia, or a class Ia or III antiarrhythmic
agent is present increases the risk of cardiotoxicity (1).
To the extent that therapeutic modalities like defibrillators and antiarrhythmic
drugs are effective, they nearly always come after the fact.
Part III is divided into 13 chapters covering Alcohol, CNS Depressants, Opioids, Cocaine, Marijuana, Amphetamines/Sympathomimetic Amines, Hallucinogens, Anticonvulsant and Antiarrhythmic
Drugs, Antidepressant Drugs, Neuroleptic Drugs, Carbon Monoxide/ Cyanide, Inhalants, and Metals.
Nine different types of antiarrhythmic
medications were successfully used to control arrhythmias in 11 patients, 10 involving supraventricular tachyarrhythmia.
Ventricular arrhythmias requiring increased antiarrhythmic
therapy were common in both groups.
When the man complained of chest pains in July 1991, doctors at the medical center found his pulse rate higher than normal and gave him antiarrhythmic
Nortran's RSD1235 acute-use antiarrhythmic
program is about to enter the clinical testing phase.
Blood levels of antiarrhythmic
drugs may also be checked.
The findings also reveal that the absence of efficacious antiarrhythmic
agents with strong safety profiles is likely to continue as Gilead/Menarini's anti-anginal agent Ranexa (ranolazine) is the only antiarrhythmic
drug forecasted to launch through 2021.
Heart rhythm experts generally prefer patients to have tried and failed at least one antiarrhythmic
drug, but that is not mandatory.
July 7 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launch and uptake of novel oral anticoagulants and antiarrhythmic
agents -- specifically, drugs from Boehringer Ingelheim, Bayer/Johnson & Johnson, Bristol-Myers Squibb/Pfizer and Sanofi-Aventis -- will drive the atrial fibrillation drug market to increase more than eight-fold, from $843 million in 2009 to $6.
CABANA (Catheter Ablation Versus Antiarrhythmic
Drug Therapy for Atrial Fibrillation) is randomizing roughly 3,000 patients with all types of symptomatic atrial fibrillation--paroxysmal, persistent, and long-standing persistent--to left atrial catheter ablation, antiarrhythmic
drug therapy, or rate control medication.